A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)-Reference-Cited by-同舟云学术

A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Published:2022-01-31 Issue:1 Volume:7 Page:35-38
ISSN:2364-768X
Container-title:Pleura and Peritoneum
language:en
Short-container-title:

Author:

Ezanno Anne-Cecile¹^ORCID,Malgras Brice¹,Aoun Olivier²,Delarge Amaury³,Doreille Alice⁴,Pocard Marc⁵

Affiliation:

1. Department of Gastrointestinal and Endocrine Surgery , Bégin Military Hospital , St Mandé , France

2. 46th Medical Unit, 5th Armed Forces Medical Center , Strasbourg , France

3. Department of Acute Care Unit , Bégin Military Hospital , St Mandé , France

4. Department of Nephrology , Tenon Hospital , Paris , France

5. Department of Gastrointestinal and Cancerology , Pitié Salpetrière Hospital , Paris , France

Abstract

Abstract Objectives Oxaliplatin immune-induced syndrome (OIIS) was recently recognized as an uncommon complication of oxaliplatin therapy. Methods We report an exceptionally OIIS after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Results Our patient developed a severe OIIS probably related to the intraperitoneal administration of oxaliplatin. Specific tests were performed and detected high-titer antibodies to oxaliplatin. Conclusions The OIIS is a rare. Physicians had to be aware of that clinical situation because it could be reversible, even in case of peritoneal advanced disease, and ICU treatment is justified.

Publisher

Walter de Gruyter GmbH

Subject

Internal Medicine

Link

https://www.degruyter.com/document/doi/10.1515/pp-2021-0138/pdf

Reference14 articles.

1. Bencardino, K, Mauri, G, Amatu, A, Tosi, F, Bonazzina, E, Palmeri, L, et al.. Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study. Clin Colorectal Cancer 2016;15:213–21. https://doi.org/10.1016/j.clcc.2016.02.001.

2. George, JN, Nester, CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:1847–8. https://doi.org/10.1056/NEJMra1312353.

3. Al-Nouri, ZL, Reese, JA, Terrell, DR, Vesely, SK, George, JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125:616–8. https://doi.org/10.1182/blood-2014-11-611335.

4. Dumont, F, Senellart, H, Pein, F, Campion, L, Glehen, O, Goere, D, et al.. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design. Pleura Peritoneum 2018;3:20180120. https://doi.org/10.1515/pp-2018-0120.

5. de Gramont, A, Figer, A, Seymour, M, Homerin, M, Hmissi, A, Cassidy, J, et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2000;18:2938–47. https://doi.org/10.1200/jco.2000.18.16.2938.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework;British Journal of Surgery;2022-09-03